The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

Nuvation Bio (NYSE:NUVB) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its oral ...

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

Tyrosine kinase inhibitors (TKIs) are used for the targeted treatment of cancer. TKIs produce a range of serious adverse events requiring careful patient management to maintain treatment benefit ...

The FDA approved taletrectinib (Ibtrozi)-- a next-generation oral ROS1 tyrosine kinase inhibitor (TKI) -- for the treatment ...

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer ...

There are conflicting data regarding the effects of TK inhibitors on tumor immunity (Table 2). Some reports demonstrated the immunostimulatory effects of a TK inhibitor, but others reported the ...

Regulatory authorities issued precautionary recommendations following the ORAL Surveillance trial, which demonstrated an ...